Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein manufacturing for vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming Third Quarter 2024 financial results release and corporate update conference call scheduled for Tuesday, November 12, 2024, at 5:00 p.m. Eastern Time. The conference call will be accessible via toll-free and international dial-in numbers, with a webcast option available. Investors can submit questions for the Q&A session via email to ir@dyadic.com prior to the call.
Dyadic International (NASDAQ: DYAI), una società biotecnologica specializzata nella produzione su larga scala di proteine per vaccini, terapie e applicazioni non farmaceutiche, ha annunciato il rilascio dei risultati finanziari del terzo trimestre 2024 e la conferenza di aggiornamento aziendale programmata per martedì 12 novembre 2024, alle 17:00 ora orientale. La conferenza sarà accessibile tramite numeri telefonici gratuiti e internazionali, con un'opzione di webcast disponibile. Gli investitori possono inviare domande per la sessione di domande e risposte via email a ir@dyadic.com prima della chiamata.
Dyadic International (NASDAQ: DYAI), una empresa de biotecnología especializada en la fabricación de proteínas a gran escala para vacunas, terapias y aplicaciones no farmacéuticas, ha anunciado la próxima publicación de sus resultados financieros del tercer trimestre de 2024 y la conferencia informativa corporativa programada para el martes 12 de noviembre de 2024, a las 5:00 p.m. hora del este. La conferencia se podrá acceder a través de números de marcado gratuito e internacionales, con una opción de webcast disponible. Los inversores pueden enviar preguntas para la sesión de preguntas y respuestas por correo electrónico a ir@dyadic.com antes de la llamada.
다이애딕 인터내셔널 (NASDAQ: DYAI)은 백신, 치료제 및 비의약품 응용 프로그램을 위한 대규모 단백질 제조를 전문으로 하는 생명공학 회사로, 2024년 3분기 재무 실적 발표 및 기업 업데이트 컨퍼런스 콜이 2024년 11월 12일 화요일, 동부 표준시 오후 5:00로 예정되어 있음을 발표했습니다. 이 컨퍼런스 콜은 무료 및 국제 전화번호를 통해 접근할 수 있으며, 웹캐스트 옵션도 제공됩니다. 투자자는 전화 전에 ir@dyadic.com으로 이메일을 통해 Q&A 세션에 대한 질문을 제출할 수 있습니다.
Dyadic International (NASDAQ: DYAI), une entreprise biotechnologique spécialisée dans la fabrication de protéines à grande échelle pour les vaccins, les thérapies et les applications non pharmaceutiques, a annoncé la prochaine publication de ses résultats financiers du troisième trimestre 2024 et la conférence de mise à jour de l'entreprise prévue pour mardi 12 novembre 2024 à 17h00, heure de l'Est. La conférence sera accessible via des numéros de téléphone gratuits et internationaux, avec une option de webinaire disponible. Les investisseurs peuvent soumettre des questions pour la session de questions-réponses par e-mail à ir@dyadic.com avant l'appel.
Dyadic International (NASDAQ: DYAI), ein Biotechnologieunternehmen, das sich auf die großtechnische Proteinherstellung für Impfstoffe, Therapeutika und nicht-pharmazeutische Anwendungen spezialisiert hat, hat die bevorstehende Veröffentlichung der Finanzergebnisse für das dritte Quartal 2024 und die Unternehmensaktualisierungskonferenz bekannt gegeben, die für Dienstag, den 12. November 2024, um 17:00 Uhr Eastern Time angesetzt ist. Die Telefonkonferenz wird über gebührenfreie und internationale Einwahlnummern zugänglich sein, und es wird eine Webcast-Option angeboten. Anleger können Fragen für die Q&A-Sitzung vor der Konferenz per E-Mail an ir@dyadic.com einreichen.
- None.
- None.
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024.
Conference Call Information:
Date: Tuesday, November 12, 2024
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560
Conference ID: 13743570
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1650834&tp_key=6f648c5876. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email ir@dyadic.com prior to the conference call.
About Dyadic International, Inc.
Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the issuance of Convertible Notes and the use of proceeds thereof. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ
When will Dyadic International (DYAI) report its Q3 2024 earnings?
How can investors access Dyadic's (DYAI) Q3 2024 earnings call?